12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

iCo-007: Completed Phase II enrollment

iCo said investigators completed enrollment in the U.S. Phase II iDEAL trial to evaluate intravitreal injections of 350 and 700 µg iCo-007 alone and in combination with laser photocoagulation or ranibizumab in...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >